Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)

• Johannes M. Waldschmidt,
• Alexander Keller,
• Gabriele Ihorst,
• Olga Grishina,
• Stefan Müller,
• Dagmar Wider,
• Anna V. Frey,
• Kristina King,
• Roman Simon,
• Annette May,
• Pierfrancesco Tassone,
• Justus Duyster,
• Manfred Jung,
• Noopur Raje,
• Ralph Wäsch,
• Monika Engelhardt

Affiliations

Johannes M. Waldschmidt

Department of Haematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Germany;Comprehensive Cancer Center Freiburg (CCCF), Faculty of Medicine, University of Freiburg, Germany

Alexander Keller

Department of Haematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Germany;Comprehensive Cancer Center Freiburg (CCCF), Faculty of Medicine, University of Freiburg, Germany

Gabriele Ihorst

Clinical Trials Unit, Faculty of Medicine, University of Freiburg, Germany

Olga Grishina

Clinical Trials Unit, Faculty of Medicine, University of Freiburg, Germany

Stefan Müller

Department of Haematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Germany

Dagmar Wider

Department of Haematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Germany

Anna V. Frey

Institute of Pathology, Faculty of Medicine, University of Freiburg, Germany

Kristina King

Institute of Pharmaceutical Sciences, Faculty of Medicine, University of Freiburg, Germany

Roman Simon

Institute of Pharmaceutical Sciences, Faculty of Medicine, University of Freiburg, Germany

Annette May

Institute of Pathology, Faculty of Medicine, University of Freiburg, Germany

Pierfrancesco Tassone

Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy

Justus Duyster

Department of Haematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Germany;Comprehensive Cancer Center Freiburg (CCCF), Faculty of Medicine, University of Freiburg, Germany

Manfred Jung

Institute of Pharmaceutical Sciences, Faculty of Medicine, University of Freiburg, Germany

Noopur Raje

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA

Ralph Wäsch

Department of Haematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Germany;Comprehensive Cancer Center Freiburg (CCCF), Faculty of Medicine, University of Freiburg, Germany

Monika Engelhardt

Department of Haematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Germany;Comprehensive Cancer Center Freiburg (CCCF), Faculty of Medicine, University of Freiburg, Germany